Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27015297 | 0.95 | GBA1 (0.44) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL26721202 | 0.94 | GBA1 (0.48) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL27015161 | 0.89 | HDAC1 (0.44) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL24922950 | 0.84 | HDAC1 (0.41) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL19592512 | 0.78 | GLS (0.38) | GBA1GLS | |
| SCHEMBL13596303 | 0.77 | GLS (0.37) | GBA1GLS | |
| SCHEMBL22643804 | 0.77 | GLS (0.43) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL19535085 | 0.77 | GBA1 (0.53) | GBA1 | |
| SCHEMBL22334356 | 0.77 | DRD2 (0.47) | — | |
| SCHEMBL13596564 | 0.76 | GLS (0.38) | GBA1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016949-A1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240016949-A1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016949-A1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VSIG8, CD81, WEE1 | HDAC1 1163/4885HDAC3 904/4885HDAC4 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.